Quoin Pharmaceuticals CEO Michael Myers Acquired A Total Of 37,894 ADSs At Prices Ranging From $0.619-$0.7974 Per ADS. Similarly, COO Denise Carter Acquired A Total Of 37,735 ADSs At Prices Between $0.6253-$0.7965 Per ADS
Quoin Pharmaceuticals CEO Michael Myers Acquired A Total Of 37,894 ADSs At Prices Ranging From $0.619-$0.7974 Per ADS. Similarly, COO Denise Carter Acquired A Total Of 37,735 ADSs At Prices Between $0.6253-$0.7965 Per ADS
Quoin Pharmaceuticals (NASDAQ:QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today announced that its Chief Executive Officer, Michael Myers, and Chief Operating Officer, Denise Carter, have recently made significant purchases of the company's American Depositary Shares (ADSs), signaling their confidence in the company's growth and direction.
Quoin Pharmicals（纳斯达克股票代码：QNRX）是一家临床阶段、专注于开发和商业化罕见病和孤儿病新疗法的专业制药公司。该公司今天宣布，其首席执行官迈克尔·迈尔斯和首席运营官丹妮丝·卡特最近大量收购了该公司的美国存托股票（ADS），这表明他们对公司的增长和方向充满信心。
On September 3 and 4, 2024, Michael Myers, CEO of Quoin Pharmaceuticals, acquired a total of 37,894 ADSs at prices ranging from $0.619 to $0.7974 per ADS. Similarly, COO Denise Carter acquired a total of 37,735 ADSs between September 3 and 4, 2024, at prices between $0.6253 and $0.7965 per ADS. These insider purchases reflect the leadership's strong confidence in Quoin's growth trajectory and commitment to delivering long-term value to shareholders as the company advances its mission to address unmet needs in underserved patient populations globally.
2024年9月3日和4日，Quoin Pharmicals首席执行官迈克尔·迈尔斯共收购了37,894张ADS，价格从每张ADS0.619美元到0.7974美元不等。同样，首席运营官丹尼斯·卡特在2024年9月3日至4日期间共收购了37,735张ADS，价格在每份广告0.6253美元至0.7965美元之间。这些内幕收购反映了领导层对Quoin增长轨迹的坚定信心，以及在公司推进其解决全球服务不足患者群体未满足需求的使命的过程中，为股东创造长期价值的承诺。
